TICKERNERD
Menu
TMCITMCIHealthcare · Medical Devices

TMCI Stock Forecast: Treace Medical Concepts, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$4.68
+8.58% on the day

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. hold a median 12-month price target of $4 — -14.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$279.6M
Ticker Nerd rank
53 / 100
Median analyst target
$4.00
Analysts covering
5
Total return, dividends reinvested
1W
+14.7%
1M
+11.2%
YTD
+91.0%
1Y
−12.4%
From 52W high
−39.2%
From 52W low
+290.0%
$1.20
$7.70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMCI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Treace Medical Concepts, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Revisions
78
Quality
65
Size
63
Value
43
Issuance
35
Momentum
34
Growth
32
Volatility
13

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (13): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Treace Medical Concepts, Inc. — and when they’d sell — is the membership.

Wall Street

TMCI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMCI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26TMCIHigh $7.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
1 Buy3 Hold1 Sell
Low $3.00Median $4.00High $7.00

The green dot is the last close — the median target sits −14.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 July 2026Truist SecuritiesMaintainsHold$2.00 → $4.00
2 Mar 2026Lake StreetMaintainsBuy—
7 Jan 2026StifelMaintainsHold—
18 Dec 2025Truist SecuritiesMaintainsHold—
10 Nov 2025Truist SecuritiesReiteratesHold—
7 Nov 2025BTIGDowngradeNeutral—
7 Nov 2025JP MorganDowngradeUnderweight—
7 Nov 2025UBSMaintainsNeutral—
15 Oct 2025Truist SecuritiesMaintainsHold—
4 Sept 2025Truist SecuritiesMaintainsHold—
8 Aug 2025StifelMaintainsHold—
8 Aug 2025UBSMaintainsNeutral—
9 May 2025UBSMaintainsNeutral—
11 Apr 2025Truist SecuritiesMaintainsHold—
13 Mar 2025Truist SecuritiesMaintainsHold—
3 Mar 2025Truist SecuritiesMaintainsHold—
31 Dec 2024Lake StreetInitiatesBuy—
18 Dec 2024Truist SecuritiesMaintainsHold—
6 Nov 2024StifelMaintainsHold—
14 Oct 2024Truist SecuritiesMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TMCI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Treace Medical Concepts, Inc. (TMCI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.6×

Cheaper than 89% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
3.6×

Cheaper than 29% of US stocks

EV / EBITDA
−6.3×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−10.2%

Higher than 16% of US stocks

Earnings growth (YoY)
−10.2%

Higher than 26% of US stocks

Gross margin
79.3%

Higher than 90% of US stocks

Operating margin
−36.4%

Higher than 19% of US stocks

Net margin
−29.4%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−66.9%

Higher than 18% of US stocks

Return on assets
−17.9%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TMCI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TMCITreace Medical Concepts, Inc.$279.6M
53
TLSITriSalus Life Sciences, Inc.$271.5M
31
SGHTSight Sciences, Inc.$284.1M
67
SENSSenseonics Holdings, Inc.$262.6M
29
RXSTRxSight, Inc.$248.8M
53
CVCapsoVision, Inc.$327.9M
18
MASS908 Devices, Inc.$328.6M
79
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMCI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TMCI news & analysis

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 24 July 2026negative

A law firm has announced that it is contacting Treace Medical Concepts, Inc. shareholders regarding potential breaches of fiduciary duties by company insiders, offering to discuss their legal rights at no cost.

Why it matters — TMCI watchers would care because this raises the possibility of legal action against the company's leadership over alleged breaches of their duties to shareholders.

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

GlobeNewsWire · 24 July 2026neutral

Treace Medical Concepts announced it will release its second quarter 2026 financial results before trading opens on August 7, 2026, with a conference call hosted by management at 8:00 am ET that same day.

Why it matters — The upcoming earnings release and conference call will provide investors and analysts with the company's latest financial performance and operational update for the quarter.

FAQ

Frequently asked questions about TMCI stock

What is the TMCI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMCI stock a buy right now?

Of the 5 analysts covering Treace Medical Concepts, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Treace Medical Concepts, Inc. 53 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMCI?

As at 1 Aug 2026, Treace Medical Concepts, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will TMCI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -14.5% from the last close, and Ticker Nerd's factor model ranks Treace Medical Concepts, Inc. 53 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMCI stock forecast for 2030?

No analyst covering Treace Medical Concepts, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMCI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $7 over the next 12 months.

How has TMCI stock performed over the past year?

Treace Medical Concepts, Inc. returned -12.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Treace Medical Concepts, Inc. do?

Treace Medical Concepts Inc. specializes in medical device development, focusing primarily on orthopedic solutions.

What is the latest news on TMCI?

The most recent item we track (PRNewsWire, 24 July 2026): "Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". A law firm has announced that it is contacting Treace Medical Concepts, Inc. shareholders regarding potential breaches of fiduciary duties by company insiders, offering to discuss their legal rights at no cost.

Company

About Treace Medical Concepts, Inc.

Treace Medical Concepts Inc. specializes in medical device development, focusing primarily on orthopedic solutions. Its flagship product is the Lapiplasty 3D Bunion Correction System, designed to address common deformities associated with bunions. This innovative system allows for precise correction in three dimensions, providing a unique, cutting-edge solution in the podiatric surgery field. Targeting hospitals, surgeons, and healthcare providers, Treace Medical Concepts plays a significant role in the medical sector by offering improved patient outcomes and recovery experiences. Headquartered in Ponte Vedra, Florida, the company supports its distribution through a strong network of sales representatives and medical partnerships in the United States. By integrating research and technology into its product design, Treace Medical Concepts Inc. contributes to advancements in surgical techniques, positioning itself as a pivotal player within the healthcare and medical device industry.

CEO Mr. John T. Treace · 450 employees · United States · https://www.treace.com